Skip to main content

Kasinger James R.'s Form 4 filing

CRISPR Therapeutics AG (CRSP) · filed Mar 24, 2026

Accession no.
0001193125-26-122274
Filed
Mar 24, 2026
Trade date
Mar 20-23, 2026
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 3 derivative transactions. Open-market sales total $148.9K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kasinger James R.CIK 0001708172Officer (General Counsel and Secretary)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 20, 2026Common SharesMOption exerciseAcquired+6,250–F2–97,490Direct
Mar 23, 2026Common SharesSSaleDisposed−3,182$46.78−$148,853.9694,308Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 20, 2026Common SharesAGrant or awardAcquired+38,499$0.00$038,499Direct
Mar 20, 2026Common SharesAGrant or awardAcquired+25,000$0.00$025,000Direct
Mar 20, 2026Common SharesMOption exerciseDisposed−6,250–F2–12,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)